賽多利斯 Sartorius  百得 Biohit  www.biohit.com www.biohitchina.com
Biohit(芬蘭百得)是一家跨國生物科技公司，開發(fā)，生產(chǎn)和市場(chǎng)，如移液器和吸頭以及診斷測(cè)試和分析系統(tǒng)的液體處理產(chǎn)品。
我們的產(chǎn)品用于研究，衛(wèi)生保健和全球?qū)嶒?yàn)室。

●成立于1988年Suovaniemi教授 
●業(yè)務(wù)范圍：液體處理和診斷
●總部設(shè)在芬蘭赫爾辛基。 
●附屬公司位于法國，德國，英國，俄羅斯，印度，中國， 日本和美國。 在新加坡有一個(gè)代表處。
●生產(chǎn)工廠位于芬蘭和中國。 
●Biohit(芬蘭百得)的產(chǎn)品銷往約70個(gè)國家的450個(gè)分銷商。

創(chuàng)新和專利
Biohit(芬蘭百得)不斷地致力于創(chuàng)新和發(fā)展。 百得以其新的技術(shù)，產(chǎn)品和服務(wù)及研究成果用于開發(fā)的早期發(fā)現(xiàn)和預(yù)防疾病的安全和符合成本效益的實(shí)驗(yàn)室工作以及診斷測(cè)試的液體處理解決方案。
產(chǎn)品包括用于研究機(jī)構(gòu)，醫(yī)療保健和工業(yè)實(shí)驗(yàn)室和手動(dòng)、電動(dòng)移液器，吸頭并提供使用技巧以及維修和校準(zhǔn)服務(wù)。

Biohit(芬蘭百得)全球集團(tuán)
本集團(tuán)成員來自11個(gè)國家約370人。 總部設(shè)在芬蘭赫爾辛基，在法國，德國，英國，俄羅斯，印度，中國，日本和美國的分公司，并在新加坡設(shè)有代表處。 此外，Biohit(芬蘭百得)的產(chǎn)品銷往約70個(gè)國家的450個(gè)分銷商。

2006年芬蘭百得實(shí)驗(yàn)室儀器（中國）有限公司(BiohitChina)成立，作為在亞太地區(qū)唯一一家子公司，百得中國(BiohitChina)將持續(xù)發(fā)揚(yáng)不斷創(chuàng)新的品牌精神，并承諾將最好的產(chǎn)品和最優(yōu)質(zhì)的服務(wù)帶到中國 ！
2011年賽多利斯(Sartorius)收購芬蘭百得(Biohit )移液器業(yè)務(wù) 

百得(Biohit)上海分公司
地址：中國上海延安西路65號(hào)國際貴都大酒店辦公樓501室
電話：+86-21-62485589
傳真：+86-21-62487786
郵編：200040
郵箱：info@biohitchina.com

Biohit is a globally operating biotechnology company that develops, manufactures and markets liquid handling products such as pipettes and pipette tips as well as diagnostic tests and analysis systems.
Our products are used by research, health care and industrial laboratories world wide.
Established in 1988 by Professor Osmo Suovaniemi 
Business areas: Liquid handling and Diagnostics 
Headquartered in Finland, Helsinki. 
Subsidiaries are located in France, Germany, the UK, Russia, India, China, Japan and the USA. There is a representative office in Singapore.
Production plants are located in Finland and China. 
Biohit's products are sold by approximately 450 distributors in 70 countries. 
Biohit Oyj's share (BIOBV) is quoted on NASDAQ OMX Helsinki since June1999, Small cap/Healthcare.
Innovations and patents
Biohit’s operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective liquid handling solutions for laboratory work as well as diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.

Business segments
Liquid handling
Products include electronic and mechanical pipettes, disposable tips as well as pipette maintenance and calibration services for research institutions, healthcare and industrial laboratories.
Diagnostics
Comprises products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. The Acetium innovation was developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. The key objective of the diagnostics business is to prevent diseases of the gastrointestinal tract.

Biohit Group worldwide
The Biohit Group employs around 370 people in eleven countries. The company is headquartered in Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia, India, China, Japan and the USA, and a representative office in Singapore. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries.

Biohit Oyj on the stock exchange
Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. More information about the share and financials is available in the Investors section of this site.